Volume 5 Number 6 July 2004
This issue includes reports from the recent resistance meeting in Tenerife – in which we include reviews of the research with the relevance to clinical practice – and Gareth Hardy provides an overview of the highly specialised Keystone meeting that took place in April.
We also round up some of the recent developments in international access to treatment. In the meantime, alarms were raised following the announcement on May 27th that the WHO had removed two Cipla products from its prequalification list: 3TC, manufactured as Lamivir and the AZT/3TC fixed dose combination, manufactured as Duovir, due to concerns over a bioequivalence study.
Although a gift to many detractors of generic antiretrovirals, a spokeswomen from MSF explained: “The fact that there is ongoing monitoring of drugs on the prequalification list by the WHO should be seen as a sign of an efficient process”, Cipla must submit new data and we should expect a result by the end of July.
Our next double issue will be August/September and will cover the World AIDS Conference taking place in Bangkok from 11-16 July. The programme for this meeting is now online at: